Top

Published in:

01-12-2017 | Case Based Review

Use of eculizumab in a systemic lupus erythemathosus patient presenting thrombotic microangiopathy and heterozygous deletion in CFHR1-CFHR3. A case report and systematic review

Authors: Maria Izabel de Holanda, Luis Cristóvão Pôrto, Teresa Wagner, Luis Fernando Christiani, Lilian M. P. Palma

Published in: Clinical Rheumatology | Issue 12/2017

Abstract

The association of thrombotic microangiopathy (TMA) with systemic lupus erythematosus (SLE) has been described in 0.5 to 10% of cases, and patients present worse outcome. TMA is described as the association of microangiopathic hemolytic anemia, thrombocytopenia, and an organ injury, frequently the kidney. This study describes a successful case of use of eculizumab in a patient with SLE and TMA refractory to standard therapy, and provides a literature review. Case description and search in PubMed and MEDLINE using systemic lupus erythemathous and/or antiphospholipid syndrome (APS) and eculizumab retrieved 15 case reports. Eighteen-year-old female presented acute renal failure and TMA and was diagnosed with SLE. Steroids and IV cyclophosphamide were started together with plasma exchange. After 55 days, she still persisted with microangiopathic anemia, thrombocytopenia, and anuria, and eculizumab was introduced. She had rapid improvement in hematological parameters, and dialysis was discontinued 25 days after the first dose. Genetic analysis showed large heterozygous deletion encompassing the entire CFHR1 and CFHR3, a finding previously associated with patients presenting atypical hemolytic-uremic syndrome (aHUS). Twenty patients who received eculizumab with SLE and/or APS have been published to date: 11 were female and mean age at presentation was 31 years. Seven out of the 20 patients presented only SLE, 5 patients only APS and 8 patients both SLE and APS. Eighteen patients underwent plasma exchange, with a mean of 20 (4–120) sessions per patient. Thirteen patients received rituximab. Hematological response was evident in 100% and kidney recovery in 85% of patients. The terminal complement blockade with eculizumab is an optional treatment for patients with SLE and/or APS presenting TMA and refractory to current immunosuppression therapies. Genetic testing may help recognize patients with aHUS and SLE/APS and therefore help to determine length of treatment with eculizumab.

Appel GB, Pirani CL, D'Agati V (1994) Renal vascular complications of systemic lupus erythematosus. J Am Soc Nephrol 4(8):1499–1515PubMed

Banfi G, Bertani T, Boeri V et al (1991) Renal vascular lesions as a marker of poor prognosis in patients with lupus nephritis. Gruppo Italiano per lo Studio della Nefrite Lupica (GISNEL). Am J Kidney Dis 18(2):240–248CrossRefPubMed

Tsumagari T, Fukumoto S, Kinjo M, Tanaka K (1985) Incidence and significance of intrarenal vasculopathies in patients with systemic lupus erythematosus. Hum Pathol 16(1):43–49CrossRefPubMed

Hu WX, Liu ZZ, Chen HP, Zhang HT, Li LS, Liu ZH (2010) Clinical characteristics and prognosis of diffuse proliferative lupus nephritis with thrombotic microangiopathy. Lupus 19(14):1591–1598CrossRefPubMed

Vieregge GB, Harrington TJ, Andrews DM, Carpintero MF, Green DF, Nayer A (2013) Catastrophic antiphospholipid syndrome with severe acute thrombotic microangiopathy and hemorrhagic complications. Case Rep Med 2013:915309CrossRefPubMedPubMedCentral

Erkan D, Aguiar CL, Andrade D et al (2014) 14th International Congress on Antiphospholipid Antibodies: task force report on antiphospholipid syndrome treatment trends. Autoimmun Rev 13(6):685–696CrossRefPubMed

Rodriguez-Pinto I, Espinosa G, Cervera R (2015) Catastrophic APS in the context of other thrombotic microangiopathies. Curr Rheumatol Rep 17(1):482CrossRefPubMed

Strakhan M, Hurtado-Sbordoni M, Galeas N, Bakirhan K, Alexis K, Elrafei T (2014) 36-year-old female with catastrophic antiphospholipid syndrome treated with eculizumab: a case report and review of literature. Case Rep Hematol 2014:704371PubMedPubMedCentral

Lonze BE, Zachary AA, Magro CM et al (2014) Eculizumab prevents recurrent antiphospholipid antibody syndrome and enables successful renal transplantation. Am J Transplant 14(2):459–465CrossRefPubMed

10.

Nesher G, Hanna VE, Moore TL, Hersh M, Osborn TG (1994) Thrombotic microangiographic hemolytic anemia in systemic lupus erythematosus. Semin Arthritis Rheum 24(3):165–172CrossRefPubMed

11.

Li QY, Yu F, Zhou FD, Zhao MH (2016) Plasmapheresis is associated with better renal outcomes in lupus nephritis patients with thrombotic microangiopathy: a case series study. Medicine (Baltimore) 95(18):e3595CrossRef

12.

Legendre CM, Licht C, Loirat C (2013) Eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 369(14):1379–1380PubMed

13.

Hadaya K, Ferrari-Lacraz S, Fumeaux D et al (2011) Eculizumab in acute recurrence of thrombotic microangiopathy after renal transplantation. Am J Transplant 11(11):2523–2527CrossRefPubMed

14.

Shapira I, Andrade D, Allen SL, Salmon JE (2012) Brief report: induction of sustained remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizumab. Arthritis Rheum 64(8):2719–2723CrossRefPubMed

15.

Canaud G, Kamar N, Anglicheau D et al (2013) Eculizumab improves posttransplant thrombotic microangiopathy due to antiphospholipid syndrome recurrence but fails to prevent chronic vascular changes. Am J Transplant 13(8):2179–2185CrossRefPubMed

16.

Kronbichler A, Frank R, Kirschfink M et al (2014) Efficacy of eculizumab in a patient with immunoadsorption-dependent catastrophic antiphospholipid syndrome: a case report. Medicine (Baltimore) 93(26):e143CrossRef

17.

Coppo R, Peruzzi L, Amore A et al (2015) Dramatic effects of eculizumab in a child with diffuse proliferative lupus nephritis resistant to conventional therapy. Pediatr Nephrol 30(1):167–172CrossRefPubMed

18.

Bakhtar O, Thajudeen B, Braunhut BL et al (2014) A case of thrombotic microangiopathy associated with antiphospholipid antibody syndrome successfully treated with eculizumab. Transplantation 98(3):e17–e18CrossRefPubMed

19.

Zikos TA, Sokolove J, Ahuja N, Berube C (2015) Eculizumab induces sustained remission in a patient with refractory primary catastrophic antiphospholipid syndrome. J Clin Rheumatol 21(6):311–313CrossRefPubMed

20.

Wig S, Chan M, Thachil J, Bruce I, Barnes T (2016) A case of relapsing and refractory catastrophic anti-phospholipid syndrome successfully managed with eculizumab, a complement 5 inhibitor. Rheumatology (Oxford) 55(2):382–384CrossRef

21.

El-Husseini A, Hannan S, Awad A, Jennings S, Cornea V, Sawaya BP (2015) Thrombotic microangiopathy in systemic lupus erythematosus: efficacy of eculizumab. Am J Kidney Dis 65(1):127–130CrossRefPubMed

22.

Pickering MC, Ismajli M, Condon MB et al (2015) Eculizumab as rescue therapy in severe resistant lupus nephritis. Rheumatology (Oxford) 54(12):2286–2288

23.

Raufi AG, Scott S, Darwish O et al (2016) Atypical hemolytic uremic syndrome secondary to lupus nephritis, responsive to eculizumab. Hematol Rep 8(3):6625CrossRefPubMedPubMedCentral

24.

Bermea RS, Sharma N, Cohen K, Liarski VM (2016) Use of eculizumab in atypical hemolytic uremic syndrome, complicating systemic lupus erythematosus. J Clin Rheumatol 22(6):320–323CrossRefPubMed

25.

Geethakumari PR, Mille P, Gulati R, Nagalla S. (2017) Complement inhibition with eculizumab for thrombotic microangiopathy rescues a living-donor kidney transplant in a patient with antiphospholipid antibody syndrome. Transfus Apher Sci 56(3):400–403

26.

Frampton G, Hicks J, Cameron JS (1991) Significance of anti-phospholipid antibodies in patients with lupus nephritis. Kidney Int 39(6):1225–1231CrossRefPubMed

27.

Cheunsuchon B, Rungkaew P, Chawanasuntorapoj R, Pattaragarn A, Parichatikanond P (2007) Prevalence and clinicopathologic findings of antiphospholipid syndrome nephropathy in Thai systemic lupus erythematosus patients who underwent renal biopsies. Nephrology (Carlton) 12(5):474–480CrossRef

28.

Espinosa G, Bucciarelli S, Cervera R et al (2004) Thrombotic microangiopathic haemolytic anaemia and antiphospholipid antibodies. Ann Rheum Dis 63(6):730–736CrossRefPubMedPubMedCentral

29.

Tektonidou MG, Sotsiou F, Nakopoulou L, Vlachoyiannopoulos PG, Moutsopoulos HM (2004) Antiphospholipid syndrome nephropathy in patients with systemic lupus erythematosus and antiphospholipid antibodies: prevalence, clinical associations, and long-term outcome. Arthritis Rheum 50(8):2569–2579CrossRefPubMed

30.

Hernandez-Molina G, Garcia-Trejo LP, Uribe N, Cabral AR (2015) Thrombotic microangiopathy and poor renal outcome in lupus patients with or without antiphospholipid syndrome. Clin Exp Rheumatol 33(4):503–508PubMed

31.

Watanabe H, Garnier G, Circolo A et al (2000) Modulation of renal disease in MRL/lpr mice genetically deficient in the alternative complement pathway factor B. J Immunol 164(2):786–794CrossRefPubMed

32.

Pierangeli SS, Espinola RG, Liu X, Harris EN (2001) Thrombogenic effects of antiphospholipid antibodies are mediated by intercellular cell adhesion molecule-1, vascular cell adhesion molecule-1, and P-selectin. Circ Res 88(2):245–250CrossRefPubMed

33.

Daugas E, Nochy D, Huong DL et al (2002) Antiphospholipid syndrome nephropathy in systemic lupus erythematosus. J Am Soc Nephrol 13(1):42–52PubMed

34.

Nochy D, Daugas E, Droz D et al (1999) The intrarenal vascular lesions associated with primary antiphospholipid syndrome. J Am Soc Nephrol 10(3):507–518PubMed

35.

Jordan N, Chaib A, Sangle S et al (2014) Association of thrombotic microangiopathy and intimal hyperplasia with bleeding post-renal biopsy in antiphospholipid antibody-positive patients. Arthritis Care Res (Hoboken) 66(5):725–731CrossRef

36.

Erre GL, Bosincu L, Faedda R et al (2014) Antiphospholipid syndrome nephropathy (APSN) in patients with lupus nephritis: a retrospective clinical and renal pathology study. Rheumatol Int 34(4):535–541CrossRefPubMed

37.

Song D, Wu LH, Wang FM et al (2013) The spectrum of renal thrombotic microangiopathy in lupus nephritis. Arthritis Res Ther 15(1):R12CrossRefPubMedPubMedCentral

38.

Pierangeli SS, Harris EN (2003) Probing antiphospholipid-mediated thrombosis: the interplay between anticardiolipin antibodies and endothelial cells. Lupus 12(7):539–545CrossRefPubMed

39.

Cervera R, Tektonidou MG, Espinosa G et al (2011) Task force on catastrophic antiphospholipid syndrome (APS) and non-criteria APS manifestations (I): catastrophic APS, APS nephropathy and heart valve lesions. Lupus 20(2):165–173CrossRefPubMed

40.

Cohen D, Koopmans M, Kremer Hovinga IC et al (2008) Potential for glomerular C4d as an indicator of thrombotic microangiopathy in lupus nephritis. Arthritis Rheum 58(8):2460–2469CrossRefPubMed

41.

Jonsen A, Nilsson SC, Ahlqvist E et al (2011) Mutations in genes encoding complement inhibitors CD46 and CFH affect the age at nephritis onset in patients with systemic lupus erythematosus. Arthritis Res Ther 13(6):R206CrossRefPubMedPubMedCentral

42.

Bu F, Borsa NG, Jones MB et al (2016) High-throughput genetic testing for thrombotic microangiopathies and C3 glomerulopathies. J Am Soc Nephrol 27(4):1245–1253CrossRefPubMed

43.

Legendre CM, Licht C, Muus P et al (2013) Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 368(23):2169–2181CrossRefPubMed

44.

Palma LM, Langman CB (2016) Critical appraisal of eculizumab for atypical hemolytic uremic syndrome. J Blood Med 7:39–72PubMedPubMedCentral

45.

Lonze BE, Singer AL, Montgomery RA (2010) Eculizumab and renal transplantation in a patient with CAPS. N Engl J Med 362(18):1744–1745CrossRefPubMed

46.

Najafi CC, Korbet SM, Lewis EJ et al (2001) Significance of histologic patterns of glomerular injury upon long-term prognosis in severe lupus glomerulonephritis. Kidney Int 59(6):2156–2163CrossRefPubMed

47.

Licht C, Greenbaum LA, Muus P et al (2015) Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies. Kidney Int 87(5):1061–1073CrossRefPubMedPubMedCentral

Title: Use of eculizumab in a systemic lupus erythemathosus patient presenting thrombotic microangiopathy and heterozygous deletion in CFHR1-CFHR3. A case report and systematic review
Authors: Maria Izabel de Holanda
Luis Cristóvão Pôrto
Teresa Wagner
Luis Fernando Christiani
Lilian M. P. Palma
Publication date: 01-12-2017
Publisher: Springer London
Published in: Clinical Rheumatology / Issue 12/2017
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI: https://doi.org/10.1007/s10067-017-3823-2

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Use of eculizumab in a systemic lupus erythemathosus patient presenting thrombotic microangiopathy and heterozygous deletion in CFHR1-CFHR3. A case report and systematic review

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 12/2017

Reliability of ultrasound grading traditional score and new global OMERACT-EULAR score system (GLOESS): results from an inter- and intra-reading exercise by rheumatologists

Human microbiome, infections, and rheumatic disease

The therapeutic effect of probiotics on rheumatoid arthritis: a systematic review and meta-analysis of randomized control trials

Psoriatic arthritis: is it time to treat-to-target or target to treat?

Educational website incorporating rheumatoid arthritis patient needs for Latin American and Caribbean countries

Asymptomatic hyperuricemia: is it time to intervene?

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page